Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., West Point, Pennsylvania
  2. Global Clinical Development, Merck & Co., Inc., Kenilworth, New Jersey
  3. Clinical Sciences and Study Management, Merck & Co., Inc, Upper Gwynedd, Pennsylvania
  4. Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., West Point, Pennsylvania
  5. Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., West Point, Pennsylvania
  6. Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., West Point, Pennsylvania
  7. Corresponding author: Wenjun Zhong, PhD, 770 Sumneytown Pike, West Point, PA 19486 ([email protected]).
  1. Brody DJ, Pratt LA, Hughes JP. Prevalence of depression among adults aged 20 and over: United States, 2013–2016. NCHS Data Brief. 2018;303:1–8. PubMed
  2. Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111–126. PubMed CrossRef
  3. Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract. 2013;63(617):e852–e858. PubMed CrossRef
  4. Preskorn SH. Prediction of individual response to antidepressants and antipsychotics: an integrated concept. Dialogues Clin Neurosci. 2014;16(4):545–554. PubMed CrossRef
  5. Fife D, Reps J, Cepeda MS, et al. Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon. 2018;4(7):e00707. PubMed CrossRef
  6. Olfson M, Amos TB, Benson C, et al. Prospective service use and health care costs of Medicaid beneficiaries with treatment-resistant depression. J Manag Care Spec Pharm. 2018;24(3):226–236. PubMed CrossRef
  7. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17–25. PubMed
  8. Gaynes BN, Gartlehner G, Hoffman V, et al. Definition of Treatment-Resistant Depression in the Medicare Population. Technology Assessment Program. Rockville, MD: Agency for Healthcare Research and Quality; 2018.
  9. Li G, Fife D, Wang G, et al. All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. Ann Gen Psychiatry. 2019;18(1):23. PubMed CrossRef
  10. Waldo DR. Accuracy and bias of race/ethnicity codes in the Medicare enrollment database. Health Care Financ Rev. 2004;26(2):61–72. PubMed
  11. Polubriaginof FCG, Ryan P, Salmasian H, et al. Challenges with quality of race and ethnicity data in observational databases. J Am Med Inform Assoc. 2019;26(8-9):730–736. PubMed CrossRef
  12. Fife D, Feng Y, Wang MY, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277–283. PubMed CrossRef
  13. Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26(3):222–232. PubMed
  14. Demyttenaere K, Van Duppen Z. The impact of (the concept of) treatment-resistant depression: an opinion review. Int J Neuropsychopharmacol. 2019;22(2):85–92. PubMed CrossRef
  15. Bains NAS. Major Depressive Disorder. NCBI. https://www.ncbi.nlm.nih.gov/books/NBK559078/. Accessed Oct 19, 2020.
  16. Kubitz N, Mehra M, Potluri RC, et al. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882. PubMed CrossRef
  17. Nuggerud-Galeas S, Sáez-Benito Suescun L, Berenguer Torrijo N, et al. Analysis of depressive episodes, their recurrence and pharmacologic treatment in primary care patients: a retrospective descriptive study. PLoS One. 2020;15(5):e0233454. PubMed CrossRef
  18. Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel). 2010;3(1):19–41. PubMed CrossRef
  19. Katon W. Collaborative depression care models: from development to dissemination. Am J Prev Med. 2012;42(5):550–552. PubMed CrossRef
  20. Culpepper L. Misdiagnosis of bipolar depression in primary care practices. J Clin Psychiatry. 2014;75(3):e05. PubMed CrossRef
  21. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645–651. PubMed CrossRef
  22. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289. PubMed CrossRef
  23. De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421–430. PubMed CrossRef
  24. Petersen T, Hughes M, Papakostas GI, et al. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002;71(5):269–274. PubMed CrossRef
  25. Sagud M, Mihaljevic-Peles A, Uzun S, et al. The lack of association between components of metabolic syndrome and treatment resistance in depression. Psychopharmacology (Berl). 2013;230(1):15–21. PubMed CrossRef
  26. Bergman J, Miodownik C, Palatnik A, et al. Efficacy of bupropion XR in treatment-resistant elderly patients: a case series study. Clin Neuropharmacol. 2011;34(1):17–20. PubMed CrossRef
  27. Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–673. PubMed CrossRef
  28. Gerhard T, Stroup TS, Correll CU, et al. Antipsychotic medication treatment patterns in adult depression. J Clin Psychiatry. 2018;79(2):55–61. PubMed CrossRef
  29. Hinton L, Zweifach M, Oishi S, et al. Gender disparities in the treatment of late-life depression: qualitative and quantitative findings from the IMPACT trial. Am J Geriatr Psychiatry. 2006;14(10):884–892. PubMed CrossRef
  30. Burnett-Zeigler I, Kim HM, Chiang C, et al. The association between race and gender, treatment attitudes, and antidepressant treatment adherence. Int J Geriatr Psychiatry. 2014;29(2):169–177. PubMed CrossRef
  31. Bogner H, Dobransky LN, Wittink MN. Patient ethnicity and perceptions of families and friends regarding depression treatment. Ethn Health. 2008;13(5):465–478. PubMed CrossRef
  32. Alegría M, Chatterji P, Wells K, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. 2008;59(11):1264–1272. PubMed CrossRef
  33. King M, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place. 2013;20:32–38. PubMed CrossRef
  34. Columbo JA, Stone DH, Goodney PP, et al. The prevalence and regional variation of major depressive disorder among patients with peripheral arterial disease in the Medicare population. Vasc Endovascular Surg. 2016;50(4):235–240. PubMed CrossRef
  35. Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017;7(8):e017173. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe